US · Healthcare · Diagnostics & Research
EPS came in at 0.27 against a street estimate of 0.24 — a beat of 12.5%.
Analysts rate Sotera Health Co a buy (8 buy, 1 hold, 1 sell out of 10) with an average price target of $22.17.
CONFIDENT SHC beat Q2 on 8% constant currency revenue growth, raised full-year guidance on both revenue and EBITDA, and reached 3x net leverage target. New CEO Alton Shader emphasizes customer focus and cross-unit synergies. Q2 2026 Company noted higher U.S. indexation vs. primary competitor in Sterigenics; EO capacity tight in large U.S. chambers but generally adequate. Analysts probed Nelson Labs sustainability, Sterigenics competitive positioning amid EPA headwinds, and X-ray ROI. Management emphasized customer demand resilience, broad portfolio strength, and variable cost structure. Leverage target achievement and capital allocation strategy (internal growth + M&A focus) deferred to forthcoming strategic review. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| Sessa Capital, L.P | 9.48% |
| Darsana Capital Partners LP | 9.46% |
| BlackRock Inc | 8.46% |
| OZ Management LLC | 8.41% |
| Sachem Head Capital Management LP | 5.45% |
| Vanguard Capital Management, LLC | 4.26% |
| Vanguard Portfolio Management, LLC | 4.19% |
| AQR Capital Management LLC | 3.76% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $324.886 million, up from $311.312 million in third-quarter 2025. • Nine-month 2026 revenue was $9 | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net revenues rose 4.4% to $324.886 million, both as reported and on a constant currency basis, compared with Q3 2025. • Q | 2026-11-03 |
| Board / officer change · Q3 2026 SOTERA HEALTH COMPANY – FORM 8-K SUMMARY HEADLINE NUMBERS • Board size reduced from 12 to 11 directors effective August 13, 2026 • Filing date: Augu | 2026-08-14 |
| Quarterly report · Q2 2026 SOTERA HEALTH COMPANY – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total net revenues (6 months): $601.4 million (2026) vs $548.9 million (2025), +9.6% | 2026-08-06 |
| Results announced · Q3 2026 SOTERA HEALTH COMPANY – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 net revenues increased 9.2% to $321.4 million (8.0% constant currency) v | 2026-08-06 |
| Shareholder vote results · Q2 2026 SOTERA HEALTH COMPANY – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held May 21, 2026 • Company trades on NASDAQ under ticker SHC | 2026-05-22 |
| Material agreement · Q2 2026 SOTERA HEALTH COMPANY (SHC) - 8-K SUMMARY HEADLINE NUMBERS • Refinanced term loan amount: $1,415,914,725.62 in repriced term loans • Interest rate r | 2026-05-20 |
| Quarterly report · Q1 2026 SOTERA HEALTH COMPANY – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Total net revenues (Q1 2026): $280,045 thousand ($280.0 million), up 10% from $ | 2026-05-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sotera Health Co — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.